Cardiovascular Diabetology

1. Cardiovasc Diabetol24 Mar 2026

   Dynamic association between triglyceride-glucose-body mass index and hospital mortality in critically ill patients with heart failure: a multicenter retrospective cohort study

   Cohort study

2. Cardiovasc Diabetol24 Mar 2026

   Triglyceride-glucose index and mortality in critically ill patients with cardiovascular-kidney-metabolic syndrome stage 4

   Cohort study

3. Cardiovasc Diabetol24 Mar 2026

   Ancestry-specific genetics of amino acids and microbiota-related metabolites reveal causal effects on cardiometabolic disease in Chinese populations

   Cohort studyT2D & other

4. Cardiovasc Diabetol23 Mar 2026

   Joint associations of anthropometric indices and C-reactive protein-triglyceride-glucose index with incident hypertension: a stratified analysis by blood pressure level from the CHARLS, 2011–2020

   Cohort studyLipids & liver

5. Cardiovasc Diabetol23 Mar 2026

   Reamputation risk and mortality after lower-limb amputation in patients with diabetes: predictors, effects of antidiabetic medications and temporal trends

   Cohort studyComplications

6. Cardiovasc Diabetol21 Mar 2026

   Circulating cardiometabolic metabolite profiles associated with ambient air pollution and atrial fibrillation risk: a prospective cohort study

   Cohort study

7. Cardiovasc Diabetol21 Mar 2026

   Bidirectional association between non-steatotic chronic liver disease and heart disease: the potential link of insulin resistance

   Cohort study

8. Cardiovasc Diabetol19 Mar 2026

   Tryptophan metabolites and stroke risk after acute myocardial infarction in patients with and without metabolic syndrome: insights from a MACCE-based cohort

   Cohort study

9. Cardiovasc Diabetol15 Mar 2026

   Associations of cumulative exposure and dynamic trajectories of cholesterol-HDL-glucose (CHG) index with cardiovascular disease in middle-aged and older Chinese adults: a longitudinal analysis

   Cohort studyLipids & liver

10. Cardiovasc Diabetol14 Mar 2026

    Association between C-reactive protein-triglyceride-glucose index and risk of stroke in different renal function status: a national cohort study

    Cohort study

11. Cardiovasc Diabetol13 Mar 2026

    Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study

    Cohort studyT2D & other

12. Cardiovasc Diabetol12 Mar 2026

    Association of the estimated glucose disposal rate combined with a body shape index with all-cause and cardiovascular-specific mortality among individuals with cardiovascular-kidney-metabolic syndrome

    Cohort study

13. Cardiovasc Diabetol9 Mar 2026

    Comprehensive evaluation of triglyceride glucose index–a body shape index (TyG–ABSI) for incident peripheral artery disease: data-driven phenotyping and machine learning-based risk prediction in the UK Biobank

    Cohort studyLipids & liver

14. Cardiovasc Diabetol6 Mar 2026

    Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal study

    Cohort studyComplications

15. Cardiovasc Diabetol5 Mar 2026

    Association between atherosclerotic index of plasma and long-term aortic-related adverse events in type B aortic dissection patients undergoing thoracic endovascular aortic repair

    Cohort study

16. Cardiovasc Diabetol4 Mar 2026

    Nanocarrier SIroliMus-coated balloon-based percutaneous coronary intervention (PCI) versus drug-eluting stent (DES)-onLy PCI in patients with diabetes mellitus

    Meta-analysisT2D & other

17. Cardiovasc Diabetol3 Mar 2026

    Prognostic stratification of cardiovascular risk and cardiac remodeling in prediabetes: a multimodal analysis comparing ADA and WHO/IEC diagnostic criteria

    Cohort studyT2D & other

18. Cardiovasc Diabetol2 Mar 2026

    Association of the C-reactive protein–triglyceride–glucose index with metabolic dysfunction-associated steatotic liver disease and long-term all-cause and cardiovascular mortality: evidence from two nationwide prospective cohort studies

    Cross-sectional studyLipids & liver

19. Cardiovasc Diabetol2 Mar 2026

    Prognostic stratification with composite insulin resistance–inflammation biomarkers in patients with chronic kidney disease and coronary artery disease across glycemic statuses

    Cohort studyT2D & other

20. Cardiovasc Diabetol27 Feb 2026

    Circulating protein biomarkers of physical fitness associated with cardiometabolic risk in women after gestational diabetes: a PONCH study

    Cross-sectional studyDiabetes in pregnancy

21. Cardiovasc Diabetol27 Feb 2026

    Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis

    Meta-analysisT2D & other

22. Cardiovasc Diabetol25 Feb 2026

    Metabolic dysfunction-associated steatotic liver disease is associated with vascular dysfunction in type 1 diabetes

    Cross-sectional studyT1D

23. Cardiovasc Diabetol24 Feb 2026

    Novel epigenetic marks of insulin resistance trajectories in a longitudinal study of childhood obesity

    Cohort studyObesity

24. Cardiovasc Diabetol24 Feb 2026

    SGLT2 inhibitors reduce the salt sensitivity of blood pressure in type 2 diabetes via enhanced postprandial natriuresis

    Randomized controlled trialT2D & other

25. Cardiovasc Diabetol24 Feb 2026

    The cholesterol, high-density lipoprotein, and glucose (CHG) index as a novel metabolic marker for predicting adverse outcomes in myocardial infarction survivors: insights from two large prospective cohorts

    Cohort studyLipids & liver

26. Cardiovasc Diabetol22 Feb 2026

    Triglyceride glucose index—a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging

    Cohort studyLipids & liver

27. Cardiovasc Diabetol22 Feb 2026

    Erythrocytosis after SGLT2 inhibitor initiation and anticoagulated outcomes in atrial fibrillation: a real-world analysis with counterfactual modeling

    Cohort studyT2D & other

28. Cardiovasc Diabetol22 Feb 2026

    Association between estimated glucose disposal rate and cause-specific mortality among individuals with metabolic dysfunction-associated steatotic liver disease

    Cohort studyLipids & liver

29. Cardiovasc Diabetol15 Feb 2026

    Epicardial fat remodeling in end-stage heart failure with reduced ejection fraction

    Cross-sectional study

30. Cardiovasc Diabetol15 Feb 2026

    Proteomics-derived organ-specific aging clusters predict macrovascular and microvascular complications in diabetes

    Cohort studyComplications

31. Cardiovasc Diabetol14 Feb 2026

    Prognostic impact of metformin in diabetic patients undergoing a percutaneous coronary intervention (PCI): protective effect is modified by procedural complexity

    Cohort studyT2D & other

32. Cardiovasc Diabetol14 Feb 2026

    Stress hyperglycemia ratio in coronary artery disease: a systematic review and meta-analysis of severity and prognosis

    Meta-analysis

33. Cardiovasc Diabetol13 Feb 2026

    The association of C-reactive protein–triglyceride–glucose index with cardiometabolic multimorbidity in middle-aged and older adults: evidence from two cohort studies

    Cohort studyLipids & liver

34. Cardiovasc Diabetol12 Feb 2026

    Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes

    Mechanistic studyT2D & other

35. Cardiovasc Diabetol11 Feb 2026

    The shared genetic architecture underlying the autoimmune and cardiovascular disease: a multivariate genome-wide analysis

    Diagnostic or prognostic studyT1D

36. Cardiovasc Diabetol8 Feb 2026

    Cumulative exposure to the estimated glucose disposal rate and incident stroke in individuals with cardiovascular–kidney–metabolic syndrome stages 0–4: 6-year longitudinal evidence from CHARLS

    Cohort study

37. Cardiovasc Diabetol4 Feb 2026

    Association of various insulin resistance surrogate indices with aging acceleration and future risk of cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: insights from CHARLS 2011–2020 data

    Cohort study

38. Cardiovasc Diabetol4 Feb 2026

    Association of the triglyceride glucose-Chinese visceral adiposity index with incident cardiometabolic multimorbidity in middle-aged and older adults: a nationwide prospective cohort study

    Cohort studyLipids & liver

39. Cardiovasc Diabetol4 Feb 2026

    Predictive value of an integrated insulin resistance and lipometabolic score for cardiometabolic multimorbidity in older adults: a UK cohort study

    Cohort studyLipids & liver

40. Cardiovasc Diabetol3 Feb 2026

    Association of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999–2018

    Cross-sectional studyLipids & liver

All 1,291 Briefs in ExploreShowing Briefs 161–200 of 1,291, newest first